BRAF mutant (MT) colorectal cancer (CRC) accounts for 10-15% of CRC and represents the subgroup with the worst overall survival. There is an urgent need to identify strategies that hit the ‘Achilles Heel’ in poor prognostic BRAFMT CRC. Preliminary data from the host lab have shown that BRAFMT CRC cells are vulnerable to disturbances in the Endoplasmic Reticulum (ER)-specific Unfolded Protein Response (UPR) machinery.
This project has received funding from the European Union’s
Horizon 2020 research and innovation programme under grant agreement No 794047